Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Gets "Wake-Up Call" In FDA Warning Letter

This article was originally published in The Tan Sheet

Executive Summary

Perrigo prioritized correcting manufacturing problems that drew an FDA warning, advising the firm to prevent human errors with tighter quality control, according to CEO Joseph Papa

You may also be interested in...



Perrigo Sales Reach Record Highs Despite Manufacturing Restrictions

Acquisitions and new products helped Perrigo grow quarterly revenue 23% to $718 million, despite manufacturing restraints related to an FDA warning letter.

Perrigo Sales Reach Record Highs Despite Manufacturing Restrictions

Acquisitions and new products helped Perrigo grow quarterly revenue 23% to $718 million, despite manufacturing restraints related to an FDA warning letter.

Perrigo Sales Reach Record Highs Despite Manufacturing Restrictions

Acquisitions and new products helped Perrigo grow quarterly revenue 23% to $718 million, despite manufacturing restraints related to an FDA warning letter.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel